[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"botulinum-toxins-type-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:botulinum-toxins-type-a":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100609123","phase-3-a-study-of-nt-201-in-adults-with-moderate-to-severe-platysma-prominence-in-europe-platinum-eu-100609123",false,"NCT07210463","A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)","A Phase 3, Randomized, Parallel-group, Double-blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in Europe","PLATINUM EU","Inclusion Criteria:\n\n* Presence of four (medial and lateral, left and right) platysmal bands assessed at screening and baseline.\n* A score of Grade 3 ('moderate') or Grade 4 ('severe') on the MAPSD at maximum contraction by the investigator AND participant.\n\nExclusion Criteria:\n\n* Hypersensitivity or a history of allergic reaction to botulinum toxin of any serotype or any of their formulation ingredients.\n* Any medical condition that may put the participant at increased risk with exposure to botulinum toxin of any serotype, or any disorders that might interfere with neuromuscular function.\n* Any serious disease or disorder that could interfere with the safe completion of treatment or with study outcome assessments, or compromise participant safety.\n* Botulinum toxin treatment in the face (below the lower orbital rim), jawline, or neck within the last seven months.\n* History of lower face surgery, neck or chest surgery, and aesthetic procedures in the past 12 months and\u002For orthodontic procedures in the past 6 months.\n* Planned surgery or aesthetic procedures to the lower face, neck, or chest during the study period.\n* Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study products).","ALL","18 Years","65 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).",[28,29,30,31,32,33,34,35,36,37],"Neuromuscular Agents","Peripheral Nervous System Agents","Physiological Effects of Drugs","Acetylcholine Release Inhibitors","Membrane Transport Modulators","Molecular Mechanisms of Pharmacological Action","Cholinergic Agents","Neurotransmitter Agents","incobotulinumtoxinA","Botulinum Toxins, Type A",[39],"Platysma prominence","RECRUITING","2026-06-10",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":44},"2025-10-01",{"date":48,"type":22},"2027-11",{"name":50,"class":51},"Merz Aesthetics GmbH","INDUSTRY",26,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100583604","phase-4-effect-of-blood-flow-by-botulinum-toxin-injection-for-severe-peripheral-artery-occlusive-disease-100583604","NCT06878482","Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease","Effect of Increasing Blood Flow by Botulinum Toxin Local Injection for Severe Peripheral Artery Occlusive Disease: Preliminary Report","Inclusion Criteria:\n\n1. Age ≥ 20 years old\n2. Patients who have a lower extremity wound among those who have been diagnosed with moderate or severe lower extremity ischemia\n3. Patients who are unable to perform additional procedures (angioplasty, etc.) by performing peripheral vascular examination and CT angiography\n4. Wound size ≥ 1x1cm2 to ≤ 3x3cm2\n5. Patients who can follow the clinical trial procedure well and abide by the visit schedule\n6. Written informed consent to participate in the study after having fully understood the contents of the protocol and restrictions.\n\nExclusion Criteria:\n\n1. Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy\n2. Within 4 weeks before screening, aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants, anticholinergics, benzodiazepines, benzamides, tetracyclines, Rinco Those who have taken mycin antibiotics, etc.)\n3. Those taking aspirin, NSAIDs or anticoagulants within 7 days before screening\n4. Those who have received botulinum toxin preparations within 3 months before screening\n5. Angiography or CT angiography If one or more of the three major blood vessels in the lower extremity are open\n6. Cases in which blood flow to the lower extremities can be preserved by performing balloon angioplasty even if all three major blood vessels in the lower extremity are blocked\n7. Those who are currently taking steroids or immunosuppressants that affect wounds, or those who have taken them within one month of screening\n8. Those who have applied injection drugs or wound coverings that help improve wounds within 1 week of screening\n9. Women who are pregnant, lactating, planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods (women of childbearing age must be negative in the pregnancy test prior to injection).\n10. Those who are allergic or sensitive to botulinum toxin\n11. Those who have participated in another clinical trial within 30 days before screening or those who have not passed the half-life of the investigational product of the clinical trial that they participated in, whichever is longer.\n12. Those who are not suitable for this clinical trial under the judgment of other investigators","20 Years",{"count":62,"type":22},15,[64],"PHASE4","The purpose of this study is to investigate the effect of subcutaneous injection of botulinum toxin A on wound healing caused by lower extremity ischemia.",[67,68,37,69],"Chronic Ulcer of Lower Extremity","Wound","Blood Circulation",[37,68,67,69],"2025-03-11",{"date":73,"type":44},"2025-03-17",{"date":75,"type":44},"2023-04-17",{"date":77,"type":22},"2026-03-31",{"name":79,"class":80},"Yonsei University","OTHER",1]